PhenoPath Toll-free: 1.888.92.PHENO P 1.206.374.9000 F 1.206.374.9009

SPECIMEN INFORMATION Facility specimen collected at		A Quest Diagnostics Company www.phenopath.com			PHENOPATH USE ONLY		
Facility specimen collected at			REQUESTING ENTITY NAME & ADDRESS				
	Facility specimen collected at			Block(s), submitted stained slides and report will be returned to the Ordering Physician at the address/FAX listed below (unless otherwise requested):			
Collection Date Collection Time		Name (Client ID)					
		le					
Multiple specimens submitted:		Add1					
Pathology Report:			Add2				
Specimen ID Sublabel Specimen Source		City, ST Zip					
		Phone: FAX#:					
			Ordering Physician Name		NPI#		
			Ordering provider signa	iture, credentials & date	e requested (required by certain payers)		
PROGNOSTIC MARKER STUDIES FIXATION (ASCO/CAP Requirement)							
Fixative: 🗌 10% NBF (Neutral Buffered Formalin) 🗌 Other			only order those tests which are medically necessary for the diagnosis and treatment of the patient. BILLING INFO (If complete and accurate patient billing information is not provided,				
Fixation duration (please circle): <6 hours 6-72 hours >72 hours Unknown			PhenoPath may bill the requesting entity)				
Collection Time: AM/PM Time Placed in Fixative: AM/PM			BILL: Insurance Patient Requesting entity				
PATIENT INFORMATION			PO#				
Name (Last, First, MI)			*If 3 rd -party billing is requested, a copy of face sheet and front/back of patient's ins/Medicare card must be attached, or client will be billed. Direct-bill regulations prohibit PhenoPath from billing a 3 rd -party entity 1 fr equesting entity has been selected, ENTRE billing demographics MUST be documented below If pre-authorization is required but is not obtained, PhenoPath will bill the requesting entity				
DOB 🗌 Male 🗌 Female			† If requesting entity has been selected, ENTIRE billing demographics MUST be documented below If pre-authorization is required but is not obtained, PhenoPath will bill the requesting entity				
			Attn:	Entity Name			
Medical Record #	Pt #	<u> </u>	Department	Address			
			City, ST Zip				
Address		Billing Contact Phone #: FAX#:		FAX#:			
Phone			TREATING PHYSICIAN (for billing purposes, write/type in the name of the treating physician)				
Phone			Mail/fax copy of report to treating physician; IF ALL INFO BELOW IS NOT COMPLETED, report will NOT be faxed or mailed				
🗌 Inpatient 🗌 Outpatient	: 🗌 Non-Hos	pital Patient	Physician Name:				
			Facility Name:				
Person completing form			Mailing Address				
Date	Phone						
			Phone #:		FAX#:		
G/TC G/TC		G/TC	G/TC	G/TC	G/TC		
Medical Record # Address Phone Inpatient Outpatient CONTACT INFORMATION Person completing form Date G/TC G/TC Adenovirus CD10 ALK protein (p80) CD14 N/A ALK (for lung CA) CD15 Alpha-1 antitrypsin* CD20 AMACR (p504s) CD22 Amyloid Beta* CD22 Amyloid Beta* CD23 Androgen Receptor CD31 ATRX CD33 BAP1 CD34 bcl-2 (clone 124) CD34 bcl-2 (clone SP66) CD38 bcl-6 CD42 bcl-10 CD43 BCH11-b CD43 BCMA CD56 Ber-Ep4 CD57 Beta-catenin CD64 BK (blood group 8) CD68	0	$ \bigcirc Desmin \\ \bigcirc DOG1 \\ \bigcirc E-cadherin \\ \bigcirc EBV by ISH (EBE \\ \bigcirc EBV by IHC \\ \bigcirc EMA \\ \bigcirc ER (SP1) \\ \bigcirc ERG \\ \bigcirc Fascin \\ \bigcirc FoXP1 \\ \bigcirc FOXP3 \\ \bigcirc Galectin-3 \\ \bigcirc Gatrin \\ \bigcirc GATA-3 \\ \bigcirc GCDFP-15 \\ \bigcirc GFAP \\ \end{vmatrix} $	□ IgG NA IgG4, IgG4 □ MP3 □ IMP3 □ INI-1 (SMAI □ INP4B □ INP4B □ INSM1 □ Kappa by IS □ Keratin 7 □ Keratin 17* □ Keratin 20 □ Keratin 20	CD38 Myo0 Image: CD38 Myo0 <	operoxidase N/A ROS-1 D1 S-100 genin SALL4 globin* SATB2 sin A SF-1 ofilaments SMAD4 1) SM		
Bob-1 CD71 Brachyury CD79; BRG1 (SMARCA4) CD10; C-MYC CD12; Calcitonin CD13; Caldesmon CD20; Caldesmon CD20; Caletinin CD20; Caletinin CD20; Caletinin CD40; Caletinin CD40; CAMPC: CD12; Caletinin CD40; CAMPC: CD12; CAMPC: CD12; CAMPC: CD12; CAMPC: CD20; CAMPC: CD12; CAMPC: CD20; CAMPC: CD20; CO12; CD12; CAMPC: CD20; CO12; CD12;	(NCAM) (KP-1) a 3 3 7 7 7 (c-kit) monoclonal) polyclonal) pogranin A 18 errin 13 13	 Glypican-3 Granzyme B H3K27me3 HBME-1 HCG (Beta-HCG) Hep B core antig Hep B surface an HepPar1 (Hepat HER2 by IHC (no I N/A HER2 by IHC (no I N/A HER2 by IHC HGAL HHV8 HLA-DR HMS45 HSV I/II DH1 	 Keratins (0) Keratins (34) Ki-67 (MB- Ki-67 (SP6) Lambda by MA LEF1 and C tigen* Lysozyme MAGE-A4 effex) Marmaglo MART-1 (M. Merkel cell polyomavir McLH1 MCL MCL	1) N/A Pan- 11) N/A Pan- 140 Parce 171 PA 181 Parce 181 PAX5 191 PAX5 192 N/A PD-1 192 N/A PD-1 194 PHA9 194 PHA9 194 PHA9 194 PHA9 194 PHA9	reatic polypeptide TdT povirus Thrombornodulin Thyroglobulin Thyroglobulin Thyroglobulin Thyroglobulin Throglobulin Throglobulin Throglobulin Transthyretin Treponema Pallidum (Sp142) Treponema Pallidum (Sp142) Trep		
Bob-1 CD71 Brachyury CD79 BRG1 (SMARCA4) CD100 C-MYC CD120 Calcitonin CD20 Calcitonin CD200 Calvenin CD200 Calvenin CD200 Calvenin CD200 Cathepsin K CD400 CD1a CEA (no CD3 N/4 CLDN CD3 N/4 CLDN CD4 Cluster CD5 CM400 CD7 CXC12 CD8 Cyclin	(KP-1) a 3 3 7 7 (c-kit) monoclonal) nogranin A 18 erin 13 D1	 Glutamine Synth Glycophorin A Glypican-3 Granzyme B H3K27me3 HBME-1 HCG (Beta-HCG) Helicobacter pyl Hep B core antig Hep B surface an HepPar1 (Hepaton) HER2 by IHC (non 1) N/A HER2 by IHC (non 1) N/A HER2 by IHC (non 1) N/A HER2 by IHC (non 1) HGAL HHV8 HLA-DR HMS45 HSV I/II IgA IgD 	 Keratins (0) Keratins (34) Ki-67 (MB- Ki-67 (SP6) Lambda by MA LEF1 and C tigen* Lysozyme MART-1 (M. Merkel cell polyomavir MART-1 (M. Mesothelin MLH1 MNDA MSH6 MUC4 	1) N/A Pan- 11) N/A Pan- 140 Parce 141 Parce 141 Parce 141 Parce 141 Parce 142 Parce 144 Parce 154 PAX8 145 PAX8 146 PD-1 147 PD-1 147 PD-1 148 PD-1 144 PO-1 144 PO-1 144 PO-1 144 PO-1 144 PO-1	Image: Constraint of the system of the sy		
Bob-1 CD71 Brachyury CD79 BRG1 (SMARCA4) CD100 Calcitonin CD13 Calcitonin CD20 Calretinin CD101 CAlretinin CD101 Calponin CD201 Calcitonin CD101 Calretinin CD101 Carbonic Anhydrase IX CD12 Cathepsin K CEA (no CD1 CD4 CD3 N/4 CLDN CD4 Cluster CD5 CM1 CD7 CXCL1	(KP-1) a 3 3 7 7 (c-kit) monoclonal) polyclonal) polyclonal) nogranin A 18 erin 13 D1 listed in a panel may be atas may also be availa	 Glutamine Synth Glutamine Synth Glycophorin A Glypican-3 Granzyme B H3K27me3 HBME-1 HCG (Beta-HCG) Helicobacter pyl Hep B core antig Hep B surface an HepPar1 (Hepation 1) HER2 by IHC (noi) N/A HER2 by IHC (noi) N/A HER2 by IHC (run FISH if 2+) HGAL HLA-DR HMS45 HSV I/II DH1 	 Keratins (0) Keratins (34) Ki-67 (MB- Ki-67 (SP6) Lambda by MA LEF1 and C tigen* Lysozyme MAGE-A4 effex) Marmaglo MART-1 (M. Merkel cell polyomavir Mesothelin MLH1 MNDA MSH6 MUC4 	1) N/A Pan- 11) N/A Pan- IHC Paroc ISH* PAXS D2 N/A PD-L N/A PD-L PAVA D2 N/A PD-L D1 PAVA D2 N/A PD-L D2 N/A PD-L D4 PAVA D5 PO-1 D1 PAVA D2 N/A PD-L D4 PAVA D5 PO-1 D6 PAVA D7 PAVA D8 PO-1 D1 PAVA D2 N/A PD-L D4 PAVA D5 PO-1 D6 PAVA D7 PAMS US PO40 * PO40 PO40 PO40	□ TCR-6F1 TRK □ TCR-delta reatic polypeptide □ TdT povirus □ Thrombomodulin □ Thrombomodulin □ □ TAT Troxoplasma gondii 1 (CD279) □ Toxoplasma gondii 1 (22C3) □ Transthyretin 1 (28-8) □ Treponema Pallidum 1 (SP142) □ Tryptase 1 (SP263) □ TTF-1 2 □ Uroplakin 2 2 □ Varicella Zoster Virus planin (D2-40) □ Villin 0 □ Villin 0 □ Villin 0 □ WF E2) □ WT-1 tate multiplex □ ZAP-70 tate specific G = staining w/o interp ren TC = staining w/o interp		

By submitting a specimen with this requisition form, you agree:

- 1) The information provided on this form and accompanying paperwork is complete and accurate.
- 2) If the information is not accurate, and PhenoPath cannot obtain reimbursement for services that have been requested and provided, Client agrees to accept financial responsibility.
- 3) If the test order is ambiguous, PhenoPath may contact client to determine intent. Testing may be delayed.
- Requests for testing PhenoPath does NOT perform (for current test menu, consult PhenoPath's website www.phenopath.com or contact Client Services at 1.206.374.9000, or Toll-free at 1.888.92.PHENO (1.888.927.4366):
 - a) PhenoPath may forward specimens to an alternate facility for testing it does not perform, upon authorization by Client.
 - b) PhenoPath will manage return of applicable specimen to Client.
 - c) By signing the authorization form, Client agrees to pay for authorized services that are not paid for by a third party. PhenoPath can only bill for professional services provided by PhenoPath.

ICD-10 – All providers, laboratories, institutions, hospitals, and other providers ordering laboratory testing to be performed by PhenoPath Laboratories must provide all clinically relevant ICD-10-CM diagnosis codes for all testing submitted.

Direct Bill Law – Washington is a "direct-bill" state for anatomic pathology services (http://apps.leg.wa.gov/rcw/default.aspx?cite=48.43.081, RCW 48.43.081). This means that for specimens originating in the State of Washington, PhenoPath can only send a bill to the entity that ordered the services (or to the patient or their insurance).

MEDICARE COVERAGE DETERMINATIONS – PhenoPath is a Medicare participating provider, and is subject to the local coverage determinations (LCD) of the Medicare Administrative Contractor (MAC) for Jurisdiction F, Noridian Healthcare Solutions, Contractor No. 02402. Additional information can be obtained online at: https://www.noridianmedicare.com/partb/coverage/active.html.

MEDICARE MEDICAL NECESSITY REQUIREMENTS – When ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements may apply:

- 1) Only tests that are medically necessary for the diagnosis or treatment of the patient should be ordered. Medicare does not pay for screening tests, except for certain specifically approved procedures, and may not pay for non-FDA-approved tests or tests considered experimental.
- 2) If there is reason to believe that Medicare will not pay for a test, the patient should be informed, and asked to sign an Advanced Beneficiary Notice (ABN) to indicate whether he/she accepts responsibility for the cost of the test if Medicare denies payment.
- 3) The ordering physician must provide all clinically relevant ICD-10 diagnosis codes, not a narrative description, in order to support the medical necessity of each test ordered. Providing ICD-10 codes on the Requisition will avoid unnecessary phone calls to physician and client offices as well as delays in service to patients to obtain medical necessity documentation. PhenoPath may contact Client to obtain diagnosis information for reasons including, but not limited to the following:
 - A diagnosis code is not provided.
 - The provided diagnosis appears inconsistent with the patient's demographic, the patient's medical condition or the testing services being ordered.
 - The provided diagnosis does not meet the coverage criteria as supporting medical necessity for testing services covered by a Medicare LCD.
- 4) Organ- or disease-oriented panels should be billed to Medicare only when every component of the panel is medically necessary. The OIG takes the position that a physician who orders medically unnecessary tests for which Medicare reimbursement is claimed may be subject to civil penalties. PhenoPath- and client-customized panels should be billed to Medicare only when every component of the customized panel is medically necessary. PhenoPath offers groups of tests based on accepted clinical practice.

Advanced Beneficiary Notice ("ABN") – An ABN, Form CMS-R-131, is a standardized notice you must issue to a Medicare beneficiary before providing certain Medicare Part B (outpatient) or Part A (limited to hospice, home health agencies [HHAs], and Religious Nonmedical Healthcare Institutions only) items or services. You must issue the ABN when:

- You believe Medicare may not pay for an item or service;
- Medicare usually covers the item or service; and
- Medicare may not consider the item or service medically reasonable and necessary for this patient in this particular instance. You should only
 provide ABNs to beneficiaries enrolled in original (fee-for-service) Medicare. ABNs allow beneficiaries to make informed decisions about whether
 to get services and accept financial responsibility for those services if Medicare does not pay. The ABN serves as proof the beneficiary knew prior
 to getting the service that Medicare might not pay. If you do not issue a valid ABN to the beneficiary when Medicare requires it, you cannot bill the
 beneficiary for the service, and you may be financially liable if Medicare doesn't pay. You may also use the ABN as an optional (voluntary) notice to
 alert beneficiaries of their financial liability prior to providing care that Medicare never covers. ABN issuance is not required to bill a beneficiary for
 an item or service that is not a Medicare benefit and never covered.
- If you order a test that does not meet Medicare's medical necessity guidelines, it is important that you complete an ABN and have it signed by the patient at the time of service. This will allow you and PhenoPath to bill the patient for the services provided if Medicare does not reimburse us for the test(s) and if the patient has accepted the financial responsibility. Medicare defines medical necessity as services that are: reasonable and necessary, for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member, and not excluded under another provision of the Medicare Program. All services reported to the Medicare Program by healthcare professionals must demonstrate medical necessity through the use of International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnostic coding carried to the highest level of specificity for the date of service.

Physician Clinical Consultant: PhenoPath's pathologists are available to discuss appropriate testing and test ordering with ordering physicians.